Table 3 Secondary outcomes—effect of treatment on intracortical Inhibition according to intervention groups.
Mean (SD) before (B) treatment | Mean (SD) after (A) treatment | ∆-value (A-B) | Beta | SEM | CI 95% | Wald χ2 | df | P | |
|---|---|---|---|---|---|---|---|---|---|
Intra-cortical inhibition | |||||||||
a-tDCS | 0.51 (0.32) | 0.50 (0.35) | − 0.02 (0.32) | 0.10 | 0.005 | (− 0.05 to 0.85) | 0.08 | 1 | 0.77 |
s-tDCS | 0.56 (0.0.29) | 0.53 (1.02) | 0.03 (0.33)reference | ||||||
Adjusted serum BDNF index | 0.004 | 0.007 | (− 0.01 to 0.02) | 0.27 | 1 | 0.60 | |||
Site of stimulation | |||||||||
a-tDCS CB + M1 | 0.53 (0.27) | 0.50 (0.26) | − 0.05 (0.23) | − 0.03 | 0.08 | (− 0.13 to 0.19) | 0.01 | 1 | 0.91 |
a-tDCS M1 | 0.44 (0.23) | 0.39 (0.17) | − 0.09 (0.28) | − 0.05 | 0.06 | (− 0.08 to 0.18) | 1 | ||
a-tDCS CB | 0.58 (0.41) | 0.64 (0.51) | 0.12 (0.39) | 0.06 | 0.15 | (− 0.35 to 0.23) | 1 | ||
s-tDCS M1+ CB | 0.53 (0.29) | 0.52 (0.31) | 0.01 (0.33) reference | ||||||
Main effect of intervention: Wald χ2=6.90; Df=2; P=0.03 | |||||||||
Cortical salient period | |||||||||
a-tDCS | 125.63 (40.25) | 121.67 (33.81) | − 3.57 (34.65) | 27.83 | 8.66 | (− 44.81 to − 10.85) | 10.32 | 1 | 0.00 |
s-tDCS | 111.29 (25.85) | 129.22 (40.19) | 17.93 (27.34)reference | ||||||
Adjusted serum BDNF index | − 0.11 | 0.83 | (− 18.50 to 20.46) | 0.01 | 1 | 0.92 | |||
Site of stimulation | |||||||||
a-tDCS CB + M1 | 123.92 (33.46) | 121.62 (33.26) | − 2.30 (27.52) | − 20.24 | 8.76 | (− 27.24 to − 3.24) | 11.71 | 2 | <0.01 |
a-tDCS M1 | 128.20 (47.20) | 123.61 (46.18) | − 4.59 (25.98) | − 22.53 | 8.43 | (− 39.06 to − 6.00) | |||
a-tDCS CB | 124.10 (39.15) | 114.74 (29.27) | − 9.36 (28.15) | − 27.30 | 8.77 | (− 44.50 to − 10.10) | |||
s-tDCS M1+ CB | 111.28 (25.85) | 129.22 (40.36) | 17.94 (27.34) reference | ||||||
